The influence of prednisone on serum angiotensin-converting enzyme activity in patients with and without sarcoidosis

Rømer, Frode K.; Jacobsen, Finn

doi:10.1080/00365518209168100

Cited by 4 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…107*127. 128 In clinical practice, the dose of corticosteroid may be titrated against serial serum ACE measurements to control the disease in the most effective way. Similarly, the enzyme activity can be used to check the patient's compliance with treatment.IM When corticosteroid treatment is withdrawn, clinical relapse may occur and may be followed by elevated serum ACE activity.…”

Section: Angiotensin-converting Enzyme As a Prognostic Test And A mentioning

confidence: 99%

Angiotensin-Converting Enzyme: Clinical Applications and Laboratory Investigations on Serum and Other Biological Fluids

Bénéteau-Burnat

Baudin

1991

Critical Reviews in Clinical Laboratory Sciences

View full text Add to dashboard Cite

Angiotensin I-converting enzyme (ACE) is a peptidyldipeptide hydrolase that is located mainly on the luminal surface of vascular endothelial cells but also in cells derived from the monocyte-macrophage system. Physiologically, ACE is a key enzyme in the renin-angiotensin system, converting angiotensin I into the potent vasopressor angiotensin II and also inactivating the vasodilator bradykinin. Increased serum ACE activity (SACE) has been reported in pathologies involving a stimulation of the monocytic cell line, primarily granulomatous diseases. Sarcoidosis is the most frequent and the better studied of these diseases; high SACE is not only a well-established marker for the diagnosis but is also a useful tool for following its course and evaluating the effect of therapy. SACE can also be increased in nonsarcoidotic pulmonary granulomatous diseases such as silicosis and asbestosis, in extrathoracic granulomatous pathologies such as Gauchers disease and leprosis, and, to a lesser extent, in nongranulomatous disorders such as hyperthyroidism or cholestasis. On the other hand, monitoring sarcoidosis obviates the measurement of ACE activity in other biological fluids, e.g., broncho-alveolar and cerebrospinal fluids, in the search of a locoregional dissemination or dis-simulation of the disease. Decreased SACE has been reported in vascular pathologies involving an endothelial abnormality, e.g., deep vein thrombosis, and in endothelium dysfunctions related to the toxicity of chemo- and radiotherapy used in cancers, leukemias, and hematopoietic or organ transplantations. SACE is also of interest for monitoring arterial hypertension treated with specific synthetic ACE inhibitors. These various reasons for determining ACE activity have led to the development of numerous methods. The most widely used is the spectrophotometric assay using hippuryl-histidyl-leucine as substrate. Fluorimetric and radiochemical assays using both classic and novel substrates have been proposed, but they are time consuming, require special apparatus, and are not suited to automation. Kinetic spectrophotometry of furylacryloyl-phenylalanyl-glycyl-glycine hydrolysis is now used extensively because it is easy to automatize. Efforts are now required to standardize one or more of these assays. Indeed, "normal" plasma values differ not only according to the substrate, but also to the method of determination and to sex and age.

show abstract

Section: Angiotensin-converting Enzyme As a Prognostic Test And A mentioning

confidence: 99%

Angiotensin-Converting Enzyme: Clinical Applications and Laboratory Investigations on Serum and Other Biological Fluids

Bénéteau-Burnat

Baudin

1991

Critical Reviews in Clinical Laboratory Sciences

View full text Add to dashboard Cite

show abstract

Serum angiotensin-converting enzyme in sarcoidosis and psoriasis

et al. 1984

View full text Add to dashboard Cite

Untreated pulmonary sarcoidosis is associated with an increased level of serum angiotensin-converting enzyme (SACE), which is regarded as a valuable method of diagnosing sarcoidosis and measuring the activity of the disease. The level of SACE in cutaneous sarcoidosis or other skin diseases has not been clearly established. We therefore examined SACE in 31 patients with systemic sarcoidosis, including cutaneous manifestations, and 12 patients with isolated cutaneous sarcoidosis. Also, 23 patients with psoriasis were studied. The level of SACE was generally elevated only in patients with untreated systemic sarcoidosis, whereas it was normal in cutaneous sarcoidosis and psoriasis. If the level of SACE is elevated in "isolated" cutaneous sarcoidosis, systemic disease must be strongly suspected.

show abstract

Détermination de l'activité enzyme de conversion de l'angiotensine I dans le liquide céphalorachidien pour le diagnostic de la neurosarcoïdose

Baudin

Bénéteau-Burnat

Vaubourdolle

2005

Immuno-analyse & Biologie Spécialisée

View full text Add to dashboard Cite

The influence of prednisone on serum angiotensin-converting enzyme activity in patients with and without sarcoidosis

Cited by 4 publications

References 18 publications

Angiotensin-Converting Enzyme: Clinical Applications and Laboratory Investigations on Serum and Other Biological Fluids

Angiotensin-Converting Enzyme: Clinical Applications and Laboratory Investigations on Serum and Other Biological Fluids

Serum angiotensin-converting enzyme in sarcoidosis and psoriasis

Détermination de l'activité enzyme de conversion de l'angiotensine I dans le liquide céphalorachidien pour le diagnostic de la neurosarcoïdose

Contact Info

Product

Resources

About